Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.37 |
| ▸ | CTSD | P07339 | 1/20 | 0.37 |
| ▸ | KDM5C | P41229 | 1/20 | 0.37 |
| ▸ | PHF8 | Q9UPP1 | 1/20 | 0.37 |
| ▸ | KDM2A | Q9Y2K7 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16714884 | 0.80 | KDM4E (0.43) | KDM4ECTSDKDM5CPHF8KDM2A | |
| SCHEMBL1024102 | 0.77 | — | — | |
| SCHEMBL605269 | 0.76 | MEN1 (0.30) | MEN1HTTKMT2AL3MBTL1 | |
| SCHEMBL17641539 | 0.76 | MEN1 (0.34) | MEN1HTTKMT2AL3MBTL1ALDH1A1 | |
| SCHEMBL13726251 | 0.74 | ALDH1A1 (0.42) | KDM4ECTSDKDM5CPHF8KDM2A | |
| SCHEMBL17456066 | 0.73 | CTSS (0.46) | — | |
| SCHEMBL3133121 | 0.72 | MEN1 (0.33) | MEN1HTTKMT2AL3MBTL1 | |
| SCHEMBL15157369 | 0.72 | CTSD (0.34) | KDM4ECTSDKDM5CPHF8KDM2A | |
| SCHEMBL1934840 | 0.71 | KDM4E (0.41) | KDM4ECTSDKDM5CPHF8KDM2A | |
| SCHEMBL8306256 | 0.71 | MEN1 (0.33) | MEN1HTTKMT2AL3MBTL1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240360149-A1 | COMPOUND WITH ANTICANCER ACTIVITY | KYOWA KIRIN CO., LTD. (JP) | 2024-10-31 | — | — | US | disclosed |
| US-20230057177-A1 | MODIFIED PROTEINS AND PROTEIN DEGRADERS | CULLGEN (SHANGHAI), INC. (CN) | 2023-02-23 | — | — | US | disclosed |
| EP-3119778-A1 | SUBSTITUTED IMIDAZO[1,2-A]PYRIDINECARBOXAMIDES AND THEIR USE | Bayer Pharma Aktiengesellschaft (DE) | 2017-01-25 | — | — | EP | disclosed |
| US-20160368926-A1 | SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF | Aptinyx Incorporated (US) | 2016-12-22 | — | — | US | disclosed |
| US-20160122359-A1 | SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF | TENACIA BIOTECHNOLOGY (HONG KONG) CO., LIMITED (HK) | 2016-05-05 | — | — | US | disclosed |
| WO-2015140254-A1 | SUBSTITUTED IMIDAZO[1,2-A]PYRIDINECARBOXAMIDES AND THEIR USE | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2015-09-24 | — | — | WO | disclosed |
| US-20110201589-A1 | NEW BRADYKININ B1 ANTAGONISTS | EVOTEC AG (DE) | 2011-08-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160368926-A1 | SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF | GRIN1, GRIN2A, GRIN3A | KDM4E 2649/4885CTSD 3945/4885KDM5C 3849/4885 |
| US-20230057177-A1 | MODIFIED PROTEINS AND PROTEIN DEGRADERS | DDB1, DCLRE1A, MDM2 | KDM4E 786/4885CTSD 2734/4885KDM5C 911/4885 |
| US-20160122359-A1 | SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF | GRIN1, GRIN2A, GRIN2B | KDM4E 3077/4885CTSD 4322/4885KDM5C 4399/4885 |
| US-20240360149-A1 | COMPOUND WITH ANTICANCER ACTIVITY | TP53, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, RCC2 | KDM4E 4107/4885CTSD 1734/4885KDM5C 4435/4885 |
| US-20110201589-A1 | NEW BRADYKININ B1 ANTAGONISTS | BDKRB1, BDKRB2, BRS3 | KDM4E 2968/4885CTSD 1842/4885KDM5C 3330/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.